Multi-omics integration and in vitro validation identify IL4R, IMPA2, and PRR4 as key therapeutic targets in chronic rhinosinusitis with nasal polyps - Takeaways - MDSpire

Multi-omics integration and in vitro validation identify IL4R, IMPA2, and PRR4 as key therapeutic targets in chronic rhinosinusitis with nasal polyps

  • By

  • Bo Wei

  • Weigang Gan

  • Jiaxin Li

  • Feng Wang

  • Jun Wang

  • Binbin Wang

  • Jiaoyu He

  • Feng Liu

  • June 15, 2026

  • 0 min

Share

  • 1

    This study identifies IL4R, IMPA2, and PRR4 as significant therapeutic targets in chronic rhinosinusitis with nasal polyps (CRSwNP).

  • 2

    Multi-omics data integration revealed 4460 differentially expressed genes and 732 hub genes related to CRSwNP pathogenesis.

  • 3

    Machine learning analysis highlighted IL4R and IMPA2 as upregulated and PRR4 as downregulated in CRSwNP, indicating their roles in the disease.

  • 4

    In vitro experiments demonstrated that targeting IL4R and IMPA2, and overexpressing PRR4, can protect against inflammation and restore epithelial integrity.

  • 5

    The findings provide new molecular targets and potential therapeutic drugs for improving diagnosis and treatment strategies for CRSwNP.

Original Source(s)

Multi-omics integration and in vitro validation identify IL4R, IMPA2, and PRR4 as key therapeutic targets in chronic rhinosinusitis with nasal polyps

  • by Bo Wei, Weigang Gan, Jiaxin Li, Feng Wang, Jun Wang, Binbin Wang, Jiaoyu He, Feng Liu

  • June 15, 2026

Related Content

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

Consensus Guidance May Improve Sinonasal Mass Outcomes

Multidisciplinary recommendations emphasize biopsy technique, imaging, and pathology review in patients with suspected sinonasal malignancy.

Who Decides When a Doctor Steps Back?

Cognitive decline, credentialing, and why “I’ll know” often isn’t enough.